Clinical trial NCT04163302: Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
Official title: Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Lymphoma, B-Cell
Keywords: Lymphoma
Chimeric antigen receptor T cell
Chimeric antigen receptor
Immunotherapy
PD-1
CD19
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2019-11-14
Enrollment: 30
Sex: ALL
Minimum age (years): 14
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided in 3 groups by different infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
Primary purpose: TREATMENT

Brief summary: This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with relapsed/refractory B Cell Lymphoma.

Detailed description: Lymphoma is a malignant tumor originating from lymph nodes or other lymphoid tissues. It can be divided into B cells, T cells, and NK cell lymphomas depending on the origin of different lymphocytes. Among them, B cell lymphoma accounts for about 90% of lymphoma.

Chimeric antigen receptor T (CART) cells is a promising treatment for lymphoma. T lymphocytes from patients are separated and engineered with CD19-CAR, to specifically recognize and eliminate CD19-positive tumor cells. At present, many CD19CART cells therapy studies are in the stage of clinical research and have achieved significant clinical effects.

Although there are some CD9CART cells clinical trials, the therapeutic effect on lymphoma is significantly lower than that of acute leukemia. One of the reasons is that lymphoma has the nature of solid tumors, whichi has a certain immunosuppressive microenvironment. The clinical trials of anti-PD-1 antibody drugs against lymphoma also show good therapeutic efficacy. Therefore, the combination of anti-PD-1 or PD-L1 antibody and CD19CART is one of the ways to improve the therapeutic effect of CART cells.

The investigators screened PD-1 mutants that have high bind with the PD-L1 ligand, and prepared CD19CART which secretes the mutant PD-1Fc fusion protein. Preclinical studies have shown that CD19CART cells secreting mutant PD-1Fc fusion protein have a superior killing effect to CD19CART cells which does not express PD-1 fusion protein.

The trial was conducted to explore the safety and efficacy of CD19-PD1-CART cells in Relapsed/Refractory B Cell Lymphoma.

Eligibility criteria: Inclusion Criteria:

1. Male or female, aged 14 to 80 years (including 14 and 80 years old).
2. The diagnosis was Refractory/relapsed B-cell lymphoma.(Meeting 1 of the first 4 items plus item 5)

   A.Tumor shrinkage less than 50% or disease progression after 4 cycles of standard chemotherapy.

   B.Achieved CR after standard chemotherapy, but relapsed within 6 months.

   C.2 or more relapses after CR.

   D.Not suitable for HSCT, or relapse after HSCT.

   E.Subjects must have received adequate treatment in the past and the predicted survival is more than three months.
3. Patient or his or her legal guardian voluntarily participates in this stuy and signs an informed consent form.
4. Flow cytometry or immunohistochemistry showed CD19 positive in tumor cells.
5. No serious concomitant disease and major organ function is not serious abnormal.
6. ECOG physical condition score 0-3 or KPS score \> 80.
7. the test meets the following indicators:

A.ALT/AST \< 2.5 times the upper limit of normal (ULN) and total bilirubin≤34.2μmol/L.

B.Creatinine \< 176.8 μmol/L.

C.WBC≥2.5×109/L ，LY≥0.7×109/L，LY%≥15%.

D.PT/INR \< 1.7 or PT was extended by less than 4 seconds.

Exclusion Criteria:

1. Women who are pregnant or breastfeeding.
2. Patients whose tumor cell don't have positive CD19 antigen.
3. Active hepatitis B or hepatitis C, HIV/AIDS infection, any uncontrolled active infection.
4. Patients who are using steroid drugs throughout the body currently.
5. Patients who have received any gene therapy in the past.
6. Patients who are allergy to immunotherapy and related drugs.
7. Patients with heavy heart disease or poorly controlled high blood pressure.
8. Patients who received chemotherapy or radiation 4 weeks before the study began.
9. Patients who are participating in other clinical trials.

Primary outcomes:
measure: Incidence of Treatment-related Adverse Events
timeFrame: 3 years
Secondary outcomes:
measure: Overall Remission Rate(ORR) of CD19-PD1-CART cells in Lymphoma
timeFrame: 3 years
measure: Overall survival(OS) of CD19-PD1-CART cells in Lymphoma
timeFrame: 3 years
measure: Progress-free survival(PFS) of CD19-PD1-CART cells in Lymphoma
timeFrame: 3 years
measure: Rate of CD19-PD1-CARTcells in peripheral blood cells
timeFrame: 3 years
measure: Quantity of CD19-PD1-CART cells copies in peripheral blood cells.
timeFrame: 3 years
Other outcomes:
Locations:
city: Sanya
country: China
facility: Hai Nan Hospital of Chinese PLA General Hospital
state: Hainan
Study officials:
affiliation: Hainan Hospital of Chinese PLA General Hospital
name: Quanshun Wang
role: STUDY_CHAIR
affiliation: Hainan Hospital of Chinese PLA General Hospital
name: Wengshuai Zheng
role: STUDY_DIRECTOR
affiliation: Hainan Hospital of Chinese PLA General Hospital
name: Lixun Guan
role: PRINCIPAL_INVESTIGATOR
affiliation: Hainan Hospital of Chinese PLA General Hospital
name: Lu Wang
role: PRINCIPAL_INVESTIGATOR
affiliation: Hainan Hospital of Chinese PLA General Hospital
name: Yuanyuan Xu
role: PRINCIPAL_INVESTIGATOR
affiliation: Hainan Hospital of Chinese PLA General Hospital
name: Yalei Hu
role: PRINCIPAL_INVESTIGATOR
affiliation: Hainan Hospital of Chinese PLA General Hospital
name: Zhengyang Gu
role: PRINCIPAL_INVESTIGATOR
References: